Tagrisso tablets 80mg

Tagrisso (osimertinib mesylate) tablets, 80mg (YJ code: 4291045F2023, standard: 80mg x 1 tablet), manufactured by AstraZeneca, are a kinase inhibitor used to treat adults with non-small cell lung cancer (NSCLC) that has specific EGFR exon 19 deletions or exon 21 L858R mutations. It works by blocking a protein that causes cancer cells to grow and multiply, and can be used as first-line, adjuvant, or for previously treated metastatic NSCLC.